Acute Lymphoblastic Leukemia in Children.

  title={Acute Lymphoblastic Leukemia in Children.},
  author={Stephen P. Hunger and Charles G. Mullighan},
  journal={The New England journal of medicine},
  volume={373 16},
The most common cancer in childhood is now curable in 90% of patients. Current efforts are focused on devising molecular-based therapy for the subsets of acute lymphoblastic leukemia that are most resistant to current therapy. 

Figures and Tables from this paper

Resolving the Genomic Complexity of Pediatric Acute Lymphoblastic Leukemia

A large number of children diagnosed with acute lymphoblastic leukemia in the Nordic countries have had at least one promoter mutation, which is a hallmark of ALL and represents key markers for diagnosis and treatment.

Outcome of childhood acute lymphoblastic leukemia treatment in a single center in Brazil: A survival analysis study

There are few studies that demonstrate the results in Brazil and the probability of current overall survival (OS) is around 90% in developed countries.

Efficacy and toxicity of high‐risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia

Children with acute lymphoblastic leukemia (ALL) and high‐risk (HR) features have a poor outcome and are treated with HR blocks, often followed by allogenic stem cell transplantation (SCT).

Genomics in childhood acute myeloid leukemia comes of age

A Children's Oncology Group study of nearly 1,000 pediatric acute myeloid leukemia (AML) cases reveals marked differences between the genomic landscapes of pediatric and adult AML and offers

Nationwide survey of pediatric hypodiploid acute lymphoblastic leukemia in Japan

Ploidy is a highly significant prognostic factor for pediatric acute lymphoblastic leukemia (ALL). Children with hypodiploid ALL have poor outcomes despite current intensive chemotherapy. Little has

Outcomes of children and young adults with T‐cell acute lymphoblastic leukemia/lymphoma who present in critical status

Patients with T‐cell acute lymphoblastic leukemia and lymphoma (T‐ALL/LLy) commonly present with critical features such as hyperleukocytosis and mediastinal mass, which complicates completing a

Pediatric Acute Lymphoblastic Leukemia

Therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), are discussed in ONCOLOGY.

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah’s Witnesses patients: a feasible option in the age of hematopoietic growth factors

B-cell acute lymphoblastic leukemia (B-ALL) can be cured in most children and in the majority of young adults with sufficiently intensive – and myelosuppressive – combination chemotherapy regimens ...

CAR-T Cells: An Innovative Therapeutic Strategy Against Pediatric Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is a prevalent and highly progressive cancer in children and adolescents associated with an excessive production of immature lymphocytes in the bone marrow, which

Immunotherapy in Pediatric Acute Lymphoblastic Leukemia

Treatment for patients with B-ALL remains a therapeutic challenge despite successes due to multi-agent chemotherapy regiments, CNS prophylaxis and better risk stratification.



Treatment of childhood acute lymphoblastic leukemia in central America: A lower‐middle income countries experience

Five Asociación de Hemato‐Oncología de Centroamérica (AHOPCA) countries have used an adapted BFM‐based protocol for childhood acute lymphoblastic leukemia (ALL).

Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.

While relapse is the main contributor to poorer survival in DS-ALL, infection-associated TRM was increased in all protocol elements, unrelated to treatment phase or regimen.

Molecular pathogenesis of T-cell leukaemia and lymphoma

This Review focuses on the molecular mechanisms responsible for disease induction and maintenance in T-ALL and compares the physiological progression of T-cell differentiation with T- cell transformation, highlighting the close relationship between these two processes.

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

Improved risk stratification and chemotherapy have eliminated the previous independent prognostic significance of gender, CNS leukemia and translocation, whereas the post-induction level of minimal residual disease (MRD) has emerged as a new risk grouping feature.

Adolescents and young adults with acute lymphoblastic leukemia.

  • W. Stock
  • Medicine, Psychology
    Hematology. American Society of Hematology. Education Program
  • 2010
This review will describe current controversies surrounding the treatment of adolescents and young adults with ALL--a group who finds themselves in the transition from "pediatric" to "adult" treatment approaches.

Trends in childhood cancer incidence in the U.S. (1992–2004)

Examination of population‐based incidence data provides insight regarding etiology among various demographic groups and may result in new hypotheses, including Asian/Pacific Islanders and Hispanics, for whom to the authors' knowledge trends have not been previously examined.

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.

The occurrence of what the author interpreted as an "acceleration phenomenon" in the leukemic process as seen in the marrow and viscera of children with acute leukemia treated by the injection of folic acid conjugates1 and pteroyltriglutamic acid (teropterin) — and an experience gained from studies on folic .

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.

  • S. HungerXiaomin Lu W. Carroll
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
This study documents ongoing survival improvements for children and adolescents with acute lymphoblastic leukemia, emphasizing that efforts to further improve survival must be directed at both high-risk subsets and at those children predicted to have an excellent chance for cure.

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children ’ s Oncology Group Study AALL 0031

Longer-term follow-up confirms the initial observation of substantially good outcomes for children and adolescents with Ph + ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.